Literature DB >> 28730565

Landmark and longitudinal exposure-response analyses in drug development.

Chuanpu Hu1, Honghui Zhou2, Amarnath Sharma2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28730565     DOI： 10.1007/s10928-017-9534-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN： 1567-567X            Impact factor:   2.745


× No keyword cloud information.
  7 in total

Review 1.  Pattern Recognition in Pharmacodynamic Data Analysis.

Authors:  Johan Gabrielsson; Stephan Hjorth
Journal:  AAPS J       Date:  2015-11-05       Impact factor: 4.009

2.  Integrated functions for four basic models of indirect pharmacodynamic response.

Authors:  W Krzyzanski; W J Jusko
Journal:  J Pharm Sci       Date:  1998-01       Impact factor: 3.534

3.  Characterization of four basic models of indirect pharmacodynamic responses.

Authors:  A Sharma; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

4.  Latent variable indirect response modeling of categorical endpoints representing change from baseline.

Authors:  Chuanpu Hu; Zhenhua Xu; Alan M Mendelsohn; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-30       Impact factor: 2.745

5.  Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritis.

Authors:  Chuanpu Hu; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-09       Impact factor: 2.745

6.  Exposure-response modeling of clinical end points using latent variable indirect response models.

Authors:  C Hu
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-06-04

7.  Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.

Authors:  R V Overgaard; S H Ingwersen; C W Tornøe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-09-22
  7 in total
  8 in total

1.  Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis.

Authors:  Chuanpu Hu; Omoniyi J Adedokun; Liping Zhang; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-10-30       Impact factor: 2.745

2.  Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis.

Authors:  Asbjørn Nøhr-Nielsen; Theis Lange; Julie Lyng Forman; Theodoros Papathanasiou; David J R Foster; Richard N Upton; Ole Jannik Bjerrum; Trine Meldgaard Lund
Journal:  AAPS J       Date:  2020-01-27       Impact factor: 4.009

3.  Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.

Authors:  Chuanpu Hu; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-11-20       Impact factor: 2.745

4.  Variability and uncertainty: interpretation and usage of pharmacometric simulations and intervals.

Authors:  Chuanpu Hu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-08-04       Impact factor: 2.410

5.  A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

Authors:  Chuanpu Hu; Zhenling Yao; Yang Chen; Bruce Randazzo; Liping Zhang; Zhenhua Xu; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-16       Impact factor: 2.745

6.  Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab.

Authors:  Chuanpu Hu; Yan Xu; Yanli Zhuang; Benjamin Hsu; Amarnath Sharma; Zhenhua Xu; Liping Zhang; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-06-30       Impact factor: 2.745

7.  Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.

Authors:  Yi Wang; Jean-Francois Marier; Nastya Kassir; Colin Chang; Patrick Martin
Journal:  Clin Transl Sci       Date:  2020-05-26       Impact factor: 4.689

8.  Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis.

Authors:  Yang Chen; Xin Miao; Chyi-Hung Hsu; Yanli Zhuang; Alexa Kollmeier; Zhenhua Xu; Honghui Zhou; Amarnath Sharma
Journal:  Clin Transl Sci       Date:  2021-12-02       Impact factor: 4.689
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.